diabetes glucose variability stress-hyperglycaemia
Conditions
Interventions
Subjects will be randomized to either Glucerna® 1.5 kcal (Abbott, USA), the
standard enteral formula used at our ICU and the investigational enteral
feeding, or Fresubin® Energy Fibre (Fresenius, UK
Sponsors
Onze Lieve Vrouwe Gasthuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Age >= 18 years Patients with an anticipated stay of at least 24 hours of admission to the intensive care Expected to receive enteral feeding for at least 72 hours Indication for glucose regulation with insulin (according to the current glucose treatment protocol) Patient or surrogate understands and signs informed consent document
Exclusion criteria
Exclusion criteria: Patients with pre-existing contraindications to enteral feeding or to placement of a CGM system Patients previously randomised into the GluCip trial Any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the patient.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome will be the extent of glucose variability, defined as the mean absolute glucose (MAG) change (delta glucose/delta time) in mmol/l/hr, measured by continuous glucose monitoring technology. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes include: time in target range (between 6-9 mmol/l) and below and above target range, mean (sensor) glucose, standard deviation of glucose values, severe hypo- and hyperglycaemic events ( 15.0 mmol/l), amount of insulin use, daily nutritional administration, clinical gastrointestinal symptoms. | — |
Countries
Netherlands
Outcome results
None listed